Pages:
Author

Topic: [ANN][INNBC]INNOVATIVE BIORESEARCH 💚 Funding AIDS cure research*get JDM cars 🚗 - page 4. (Read 17906 times)

newbie
Activity: 150
Merit: 0
This is really an interesting project. It touches on important vital issues for today, I am glad that such promising projects are being created. I think this will be useful for many people. I think many will agree that this is an innovative project. I wish you good luck and development, I will follow the topic.
newbie
Activity: 341
Merit: 0
I wish that you guys will have a successful ICO and implement this project because it will be a big impact to everyone in the world and if these kind of platform will success in the future then one thing is for sure that people around the globe will adopt the Blockchain technology and Cryptocurrency because it can solve the problem of humanity.

EDIT.

The ICO was cancelled, the token sale (presale and ICO) never actually took place, and the tokens were airdropped as a free reward to the participants of the bounty campaign https://bitcointalksearch.org/topic/bountyinnbcinnovative-bioresearchfunding-aids-cure-researchget-jdm-cars-3385669

 
full member
Activity: 624
Merit: 101
BBOD Zero-Fee Exchange
I wish that you guys will have a successful ICO and implement this project because it will be a big impact to everyone in the world and if these kind of platform will success in the future then one thing is for sure that people around the globe will adopt the Blockchain technology and Cryptocurrency because it can solve the problem of humanity.
newbie
Activity: 341
Merit: 0
WE CAN NOW ACCOUNCE THAT WE MADE AN AMAZING PARTNERSHIP WITH THE FIXY NETWORK

Article published on CCN.

https://www.ccn.com/sell-your-tokens-loaded-on-gift-cards-and-50-000-for-selected-startup-projects/

Sell Your Tokens Loaded on Gift Cards and $50.000 for Selected Startup Projects


Advertising over Fixy Network App
One of the most important things investors should look out for when investing in an ICO is whether or not a token will be able to gain user adoption and be useful for solving problems with its application in the real world. Unfortunately, many projects are simply bad ideas from the start.

In the context of fundraising through ICO, we may see an increasing amount of fresh capital influx to crypto market capitalization as cryptocurrency gaining more exposure In the mainstream media and considering that regulation initiative by G20 countries will soon come to provide legal certainty for cryptocurrencies and protections from the prevalent ICO-related frauds.

Up until now, many investors perceive the facts that investing in ICOs is a hard thing to do. Although many are interested in contributing to ICOs, they are unable to do so because they perceive the process of getting their first crypto and its wallet as a mode of payment for ICOs are way too complicated for them.

Gift cards provided by Fixy Network will give an opportunity to people to get into the cryptocurrency-world without going through lengthy verification process since it provides a convenient shortcut. ICO’s Gift cards will be sold like online credit cards on a website, providing an easy access for everyone around the globe. After purchase, they can be claimed by mail or post.

By using Gift cards provided by Fixy Network, potential investors can invest to any ICO that uses erc20 tokens with their FIAT money and directly receive a gift card that loaded with the ICO’s token. This method gives an extremely competitive advantage for any ICO to obtain new investors since it eliminates the pain point to invest in any ICOs such as the need for buying cryptocurrency through exchanges with its fees and setting up crypto wallets which seem still perceived as complicated steps by many new investors.

New Partnerships Announcement
In this opportunity, FIxy Network is also pleased to announce 3 new partnerships after successfully secured multiple partnerships in the past :

Agentmile (agentmile.com). The world’s first decentralized CRE leasing platform powered by Al. Agentmile enables brokers and landlords to list their commercial properties on our blockchain powered MLS and offer enhanced leasing capabilities, management and reporting.

Innovative Bioresearch (innovativebioresearch.com). Innovative Bioresearch Ltd is a privately held biotech company, with the goal of bringing innovation to the field of HIV, cancer and regeneration research. In addition, the INNBC Token will be spendable to buy classic iconic JDM cars from our JDM online garage and is therefore backed by the value of actual physical goods.

More partnerships announcement is already in the pipeline and will be announced soon, stay tuned!

Fixy Exchange Listing Opportunity

Last but not least, Fixy network is looking to build an altcoin exchange and all partnership ICOs will be listed on the exchange. Altcoins exchange feature on Fixy smartphone app will provide users with ease of access and convenience, ensuring a steady growth of user numbers. Should a startup wants to list its coin on the exchange, the fee will be paid in FXY Token.

Fixy Token will be listed 8 June 2018 on popular exchanges and 25 June is token burn of 85% total supply scheduled. FXY Token price is with 2$ fixed for B2B deals. Actually it can be traded dit for 0.1$ on forkdelta.



newbie
Activity: 341
Merit: 0
newbie
Activity: 150
Merit: 0
Continue to develop this project to help heal people with AIDS. It seems that many will support this project, because this penyya bit becomes a serious problem in various countries.
full member
Activity: 381
Merit: 101
How nice to be aware of the fact that in a short time humanity will learn to fight all diseases and prevent them in advance. This is one of the few projects that we really need, which move us forward.


it would be great if this project was to develop.
his idea is very noble and it would have helped a lot to humanity.
health is the main thing in life and it improves the project itself.
member
Activity: 392
Merit: 10
How nice to be aware of the fact that in a short time humanity will learn to fight all diseases and prevent them in advance. This is one of the few projects that we really need, which move us forward.
newbie
Activity: 341
Merit: 0
WITH A RELATED EXCHANGE LISTING ANNOUNCEMENT!!!
newbie
Activity: 341
Merit: 0
BIG, BIG, BIG NEWS COMING!!!!


NEW PARTNERSHIP ANNOUNCEMENT SOON!!!
newbie
Activity: 341
Merit: 0
EDIT.

Correcting this old incorrect information so as to prevent the spread of incorrect information. The ICO was cancelled, the token sale (presale and ICO) never actually took place, and the tokens were airdropped as a free reward to the participants of the bounty campaign https://bitcointalksearch.org/topic/bountyinnbcinnovative-bioresearchfunding-aids-cure-researchget-jdm-cars-3385669
 


newbie
Activity: 341
Merit: 0
Any issue or question about the Token sale let me know.
newbie
Activity: 341
Merit: 0
So as our Token is spendable to buy jdm cars, we always monitor the market for these cars. So I just got back from a conversation with one of our contacts importing cars from Japan. The Subaru Impreza WRX Type RA LE just went up in value considerably in the recent months. Just a couple of months ago it was possible to buy one for 13k pounds, now they go for 20k pounds. This really shows that these cars are a very solid investment. Because our Token is backed by the value of these cars, this is going to preserve the INNBC Token value.

Unlike other coins that are backed just by hopes and dreams, and their price can go up and down to whatever value the market feels, our Token is backed by the value of real assets, and its price on exchanges should reflect that.
newbie
Activity: 341
Merit: 0
Any other question we are here to asnwer.
newbie
Activity: 341
Merit: 0
AIDS is currently one of the most threatening humans to the horror virus. There is no good therapy so far. Many medical experts have tried to solve the virus. Many countries’ governments have given a lot of financial support for research to overcome AIDS virus. If your project can solve this problem, ICO is not needed at all.

There is very poor funding with regard to exploring innovative solutions, take it from people who does this as a job Wink.  So many promising projects are left unfunded by government agencies. This is why ICOs can be, without any doubt, a necessary and novel tool for funding potentially vital research that would have otherwise been left to die by the academic world.

Because governments can easily dictate what researches should be funded and developed, and because this process can also be influenced by possible conflicts of interests (e.g., pharmaceutical corporations selling HIV drugs not willing to lose their marketshare if an AIDS cure is developed), ICOs can be a necessary tool for our society to decentralize the funding power from government agencies/pharmaceutical corporations to the collectivity.

The INNBC Token will be accepted as a means of payment for all our furture medical services and products.

EDIT.

Correcting this old incorrect information so as to prevent the spread of incorrect information. The ICO was cancelled, the token sale (presale and ICO) never actually took place, and the tokens were airdropped as a free reward to the participants of the bounty campaign https://bitcointalksearch.org/topic/bountyinnbcinnovative-bioresearchfunding-aids-cure-researchget-jdm-cars-3385669
 
member
Activity: 456
Merit: 15
AIDS is currently one of the most threatening humans to the horror virus. There is no good therapy so far. Many medical experts have tried to solve the virus. Many countries’ governments have given a lot of financial support for research to overcome AIDS virus. If your project can solve this problem, ICO is not needed at all.
newbie
Activity: 106
Merit: 0
New youtube review of our ICO

https://www.youtube.com/watch?v=qAQdVaJlExg
If your research will be successful, that is fantastic... good Luck
newbie
Activity: 341
Merit: 0
I've recently noticed your ICO. The point is that nobody before never invented something against AID and cancer or their inventions are useless.
What distinct you from numerous projects without any results. Why do you think that you will invent medicine against AID?

Now, in the previous post I gave you a technical explanation about why our treatment is novel and is exploring approaches never tested before. However, there is also an economic explanation why there is such an extreme lack of innovation in this field.

There is the huge business of the pharmaceutical corporations selling expensive HIV drug, which aim to make as much profit as possible off of AIDS. These companies would never support the development of a low cost AIDS cure because it would put an end to their huge profits. This is precisely why we need a project such as this one in our society.

There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations.
newbie
Activity: 341
Merit: 0
I've recently noticed your ICO. The point is that nobody before never invented something against AID and cancer or their inventions are useless.
What distinct you from numerous projects without any results. Why do you think that you will invent medicine against AID?

Actually, we have conceived a very innovative cell-based therapy for HIV that uses the SupT1 cell line as a decoy target for the HIV virus. Our approach is unique as no other therapy tried to use a permissive T cell-line as a decoy target for the HIV virus. Furthermore, this is a cell-based approach, which is something completely different than traditional drug based approaches that failed to produce an AIDS cure. So we are not in need of inventing a new solution, we just need to further develop the HIV therapy we have already conceived, completing preclinical animal research and move to human trials. I'll post some information from our website regarding our novel AIDS therapy solution.


An Overview of SupT1 Cell Infusion Therapy, our Novel Cell-Based Therapy Solution for HIV


HIV infection usually leads to a progressive decline in number and functionality of CD4+ T lymphocytes, resulting in AIDS development. As explained in Jonathan Fior’s papers [1–3], the HIV virus has a higher tropism for SupT1 cells than for primary CD4+ T cells. Several hypotheses have been proposed as an explanation, most notably the higher surface expression of CD4 and CXCR4 receptors in SupT1 cells. In addition, in vitro studies of HIV evolution show that persistent growth in the SupT1 cell line results in a less cytopathic virus with a reduced capacity for syncytium formation, a higher sensitivity to neutralization, improved replication in SupT1 cells and impaired infection of primary CD4+ T cells [4–6]. Accordingly, Jonathan Fior proposed the infusion of irradiated SupT1 cells as a cell-based HIV therapy to exploit the therapeutic potential of these phenomena [1–3]. The rationale behind this approach is that moving infection toward the inoculated cells should prevent infection and depletion of the patient’s own CD4+ T cells and, therefore, AIDS. In such a strategy, SupT1 cells would act as a “decoy target” for the HIV virus to prevent CD4+ T cell depletion as well as to render the virus less cytopathic. As previously mentioned, in vitro studies of HIV evolution show that prolonged replication in SupT1 cells renders the virus less cytopathic and more sensitive to neutralization. Accordingly, replication of the virus in the inoculated SupT1 cells should also have a vaccination effect; that is, the therapy should also induce the virus to become progressively less aggressive and harmful for the patient. The use of SupT1 cells as a decoy target for HIV has been investigated in vitro and in vivo, with interesting results [1,3]. In vitro data showed that, when primary CD4+ T cells are infected with HIV in the presence of SupT1 cells, the preferential infection of SupT1 cells can spare primary CD4+ T cells from infection and depletion. In vivo data in humanized mice showed that significantly lower viral replication (~10-fold) and potentially preserved CD4+ T cell frequency at Week 1 was scored in animals treated with SupT1 cell infusion. Of note, one animal exhibited a sustained decrease in HIV replication and CD4+ T cell depletion (no virus detected anymore at Weeks 3 and 4), a result that may hold the key to future HIV treatments. Given the urgent and global need for a cost effective cure for HIV, we believe that the millions of people infected by this terrible disease deserve highly innovative HIV cure research strategies, such as SupT1 cell infusion therapy.

In summary, these are some of the potential therapeutic benefits of this cell-based treatment that go beyond what can be achievable with traditional antiretroviral therapy (cART):

1)The vaccination effect. As previously mentioned, SupT1 cells have been shown to have a very powerful vaccination effect in vitro [4–6]. In this regard, in vitro studies of HIV evolution showed that upon prolonged replication in SupT1 cells, the X4 HIV-1 LAI virus evolves toward a less virulent phenotype with a reduced capacity for syncytium formation, thus losing the main cytopathic feature characterizing X4 strains, and most notably the virus adaptation to replicate in SupT1 cells results in gradually losing the ability to replicate in primary CD4+ T cells [4]. In addition, the variation to neutralization sensitivity after viral growth in tumor T cell lines has also been examined. Interestingly, one study reported that primary isolates that were initially resistant to neutralization acquired sensitivity to neutralization after continuous growth in tumor T cell lines, and that the sensitivity to neutralization progressively increased during the days of culturing [5]. Specifically, it was shown that after 14 days in continuous culture, 100 micrograms/mL of rsCD4 (recombinant soluble CD4) were needed to neutralize 1 TCID of primary isolate, while only 0.3 micrograms/mL of rsCD4 were needed to neutralize 1 TCID of the virus after 75 days in continuous culture. This means that there was a 300 fold increase in virus sensitivity to neutralization after prolonged replication in a tumor T cell line, which is really something remarkable. All these phenomena could therefore harbor a significant therapeutic potential that could be exploited with SupT1 cell infusion therapy to induce HIV infection to evolve into a more tractable state for therapy.

2)Potentially no organ toxicity; cART is a drug based treatment and as such is associated with organ toxicity because the drugs are metabolized by various organs. By contrast, SupT1 cell infusion is a cell-based treatment and there is no chemical substance injected into the body that needs to be metabolized, which could significantly improve the quality of the patient's life.

3)Be effective in patients in a terminal state of disease that developed drug resistant and very aggressive HIV strains. When a patient is treated with cART, the virus fights back because it strives to survive, which can result in the development of very aggressive and drug resistant HIV strains, especially in the terminal stage of the disease and in such cases cART becomes ineffective. By contrast, SupT1 cell infusion therapy provides the virus with a permissive cell-line in which it can preferentially replicate, so that a peaceful coexistence between virus and host becomes possible, which could dramatically improve the patient's health as the virus infection progressively moves toward the inoculated SupT1 cells and the virus becomes increasingly less pathogenic for its host.

4)Possible association of the treatment with novel molecular compounds such as a Vif-inhibitor to act on HIV reservoirs. The HIV-1 Vif protein is essential for viral replication in primary CD4+ T cells but not in SupT1 cells [1]. Accordingly, pharmacologic inhibition of Vif could be combined with SupT1 cell infusion to further restrict viral replication to the inoculated SupT1 cells. Considering that APOBEC3G is expressed by different cell types, such as neuronal cells, astrocytes, and macrophages [2], pharmacologic inhibition of Vif may also have the benefit of acting on HIV reservoirs in the brain and other body areas. There are several molecules with promising anti-Vif activity currently being tested [2]. Similarly, other HIV-1 accessory proteins that are not essential for replication in SupT1 cells (e.g., Vpr, Vpu, and Nef [3]) may also be the target of pharmacologic inhibition. It is important to point out that these drugs would not affect virus replication in the inoculated SupT1 cells, and therefore in combination with SupT1 cell infusion therapy, there should not be development of drug resistance normally associated with drug based treatments.

​5)A cost effective AIDS cure solution. Our mission is to provide a cost effective cure solution for AIDS. In contrast with traditional cell-based and gene-based therapies that make use of modified autologous cells and are therefore very expensive and often unpractical for a large scale application, using a standardized T cell line such as the SupT1 cell line should significantly reduce the treatment costs associated with SupT1 cell infusion therapy, allowing access to the therapy where access to traditional HIV therapies is restricted by economic and social limitations. The social and economical impacts of a low cost HIV cure solution would be enormous.

Below some considerations with regard to potential issues:

1)Safety. We take this issue very seriously and are committed to performing very rigorous preclinical research to ensure there is enough data on safety to obtain approval from regulatory agencies for human experimentation. In this regard, injection of irradiated tumor cells as a therapy is already performed in cancer vaccination. In such cases, irradiating the cells prior to inoculation has been shown to ensure treatment safety both in animal and clinical studies [7]. We used the same protocol used in cancer vaccination studies (i.e., 30 Gy of radiation dose for the cells), which resulted in safe in vivo inoculation in our animal study as well [3]. Specifically, all animals successfully survived the treatment and presence of SupT1 cells was almost undetectable at late time points, which means that irradiating the cells prior to inoculation efficiently prevented SupT1 cell replication. Furthermore, we infused high doses of cells (40 million SupT1 cells were infused weekly), which in a highly immunodeficient mouse strain would rapidly lead to animal death in case of tumor development. Therefore, based on the clinical data we already have from cancer vaccination studies, and from the results of our first animal study, we believe that meeting the safety standards required for human trials is something feasible.

2)Rejection issues. Tumors can develop because tumor cells are able to evade immune recognition. For example, SupT1 cells do not express HLA-DR, which is an antigen highly associated with immune recognition [8]. Accordingly, given the tumoral nature of SupT1 cells, they should be significantly less immunogenic than normal cells and as such should survive in the patient long enough to provide a therapeutic effect. However, it is possible that the HIV virus will eradicate the cells faster and more efficiently than the immune system itself in any case.

References

1. Fior J. An initial in vitro investigation into the potential therapeutic use of SupT1 cells to prevent AIDS in HIV-seropositive individuals. PLoS ONE. 2012;7:13.

2. Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5:753–757.

3. Fior, J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016, 4:13.

4. Das, A.T.; Land, A.; Braakman, I.; Klaver, B.; Berkhout, B. HIV-1 evolves into a nonsyncytiuminducing virus upon prolonged culture in vitro. Virology. 1999, 263:55–69.

5. Turner, S.; Tizard, R.; DeMarinis, J.; Pepinsky, R.B.; Zullo, J.; Schooley, R.; Fisher, R. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA. 1992, 89:1335–1339.

6. Moore, J.P.; Burkly, L.C.; Connor, R.I.; Cao, Y.; Tizard, R.; Ho, D.D.; Fisher, R.A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses. 1993, 9:529–539.

7. Salgia R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 2003, 21:624–630.

8. Dufresne I, et al. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab′ fragments. Biochim Biophys Acta. 1999, 1421:284-94.









newbie
Activity: 341
Merit: 0
Let me now if you have any issue with the Token sale.
I tried to register but I do not receive any confirmation mail. Tried with gmail address and with a self hosted email service. Already checked the log files, but there is no email incoming.

Hello,

EDIT.

Correcting this old incorrect information so as to prevent the spread of incorrect information. The ICO was cancelled, the token sale (presale and ICO) never actually took place, and the tokens were airdropped as a free reward to the participants of the bounty campaign https://bitcointalksearch.org/topic/bountyinnbcinnovative-bioresearchfunding-aids-cure-researchget-jdm-cars-3385669

 

Pages:
Jump to: